Amicogen, Inc.

A092040

KR7092040005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
7,680 ^KRW	-1.54%		+2.67%	+1.59%

Mar. 20	Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Beyond Cells announced that it has received KRW 3 billion in funding from Amicogen, Inc.

April 14, 2023

On April 15, 2023, Beyond Cells closed the transaction.

Latest news about Amicogen, Inc.

Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 20	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Beyond Cells announced that it has received KRW 3 billion in funding from Amicogen, Inc.	23-04-14	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Lysando Ag and Amicogen Inc. Sign General Development Agreement	22-10-18	CI
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-16	CI
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding	22-07-17	CI
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding	22-07-17	CI
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-16	CI
Amicogen, Inc. announced that it has received KRW 8.7 billion in funding	22-05-10	CI
Amicogen, Inc. announced that it expects to receive KRW 8.7 billion in funding	22-05-08	CI
Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-22	CI
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-15	CI
Amicogen, Inc. completed the acquisition of 30% stake in BIFIDO Co., Ltd from a group of shareholders.	21-09-13	CI
Amicogen, Inc. announced that it has received KRW 22.2724863 billion in funding from Lysando AG	21-09-01	CI
Amicogen, Inc. agreed to acquire a 30% stake in BIFIDO Co., Ltd from a group of shareholders for KRW 60.1 billion.	21-07-20	CI
Amicogen, Inc. agreed to acquire 8% stake in Lysando AG for KRW 28 billion.	21-07-14	CI
Amicogen, Inc. announced that it expects to receive KRW 22.2724863 billion in funding from Lysando AG	21-07-13	CI
Amicogen, Inc. announced that it has received KRW 50 billion in funding	21-06-28	CI
Amicogen, Inc. announced that it expects to receive KRW 50 billion in funding	21-06-22	CI
Beyond Cells announced that it expects to receive KRW 4.0188 billion in funding from Amicogen, Inc.	20-09-14	CI
Yoo's Pharm Corporation announced that it has received KRW 5 billion in funding from Amicogen, Inc.	20-01-14	CI
Yoo's Pharm Corporation announced that it expects to receive KRW 5 billion in funding from Amicogen, Inc.	20-01-13	CI

Amicogen, Inc. is a Korea-based company engaged in the development, production and distribution of enzymes, bio new materials and healthcare food. The Companyâs products consist of special enzymes, N-acetylglucosamine (NAG), pinitol, D-Chiro-inositol (DCI), collagen peptides (CP) and protein A chromatography resins. The Company distributes its products within domestic market and to overseas markets, including China, Japan, the United Sates, Germany and Thailand.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AMICOGEN, INC.	+1.59%	304M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B